Mascoma Corporation

Mascoma Corporation Acquires Celsys BioFuels, Inc.

Mascoma Corporation Acquires Celsys BioFuels, Inc.

November 7, 2007

Dr. Michael Ladisch joins as Chief Technology Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in advanced low-carbon biofuels, today announced the acquisition of Celsys BioFuels, Inc. Terms of the transaction were not disclosed.

BIND Therapeutics, Inc.

BIND Biosciences, Inc. Closes $16M Series B Financing Round

BIND Biosciences, Inc. Closes $16M Series B Financing Round

November 27, 2007

CAMBRIDGE, MA – November 27, 2007 – BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing “smart” therapeutic targeted nanoparticles capable of differential delivery and controlled drug release to diseased tissue, announced today that it has secured a $16 million Series B financing. BIND’s platform is based on a combinatorial technology that allows for precise engineering of optimally formulated targeted nanoparticles that substantially increase the clinical efficacy and safety of existing and new therapeutics.

LS9

LS9, the Renewable Petroleum Company, Selected by World Economic Forum as 2008 Technology Pioneer

LS9, the Renewable Petroleum Company, Selected by World Economic Forum as 2008 Technology Pioneer

November 29, 2007

President of pioneering hydrocarbon biofuels company to accept honor in Davos, Switzerland

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project

AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project

December 4, 2007

Agreement Highlights Growing Interest in Novel Biology Platform that Identifies Clinical Response of Cancer Drugs

Concert Pharmaceuticals, Inc.

CoNCERT Pharmaceuticals Appoints Dr. Ronald W. Barrett to the Company’s Board of Directors

CoNCERT Pharmaceuticals Appoints Dr. Ronald W. Barrett to the Company’s Board of Directors

December 18, 2007

LEXINGTON, Mass., December 18, 2007 – CoNCERT Pharmaceuticals Inc., the first company dedicated to creating new medicines using precision modification chemistry with the naturally-occurring element deuterium, announced today the appointment of Ronald W. Barrett, Ph.D. to its Board of Directors. Dr. Barrett is chief executive officer, co-founder and director of XenoPort, Inc. (NASDAQ: XNPT), a biopharmaceutical company focused on developing a portfolio of internally discovered products candidates for the potential treatment of central nervous system disorders.

BIND Therapeutics, Inc.

BIND Biosciences, Inc. appoints Jim Wright, PhD as Chief Scientific Officer

BIND Biosciences, Inc. appoints Jim Wright, PhD as Chief Scientific Officer

December 19, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing “smart” therapeutic targeted nanoparticles capable of controlled drug delivery to diseased tissue, announced today the appointment of Jim Wright, Ph.D., as Chief Scientific Officer.

BG Medicine, Inc.

BioImage Study Seeks to Identify Individuals at High Risk of Heart Attack or Stroke 2-3 Years before Occurrence

BioImage Study Seeks to Identify Individuals at High Risk of Heart Attack or Stroke 2-3 Years before Occurrence

December 20, 2007

Next phase of the High-Risk Plaque Initiative will leverage advances in diagnostic imaging and blood biomarker science to reduce morbidity, mortality and cost associated with cardiovascular disease

Quanterix Corporation

Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection of Prostate Cancer

Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection of Prostate Cancer

May 23, 2010

Quanterix Technology Shown To Be More Than 1,000 Times More Sensitive Than Standard Methods With Potential For Broad Application To Measure Biomarkers In Cancer, Autoimmune, and Neurological Diseases

T2 Biosystems, Inc.

T2 Biosystems Raises $15 Million in Series C Financing

T2 Biosystems Raises $15 Million in Series C Financing

May 25, 2010

Physic Ventures Leads Financing in Novel Technology to Enable Decentralized Diagnostics

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors

AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors

January 3, 2008

CAMBRIDGE, MA, January 3, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of Kenneth M. Bate, president and chief executive officer of NitroMed, Inc., to its Board of Directors.